


MedImmune Expert Speaker Interview released in run up to Immuno-Oncology Conference

SMi Group reports: Exclusive interview with Grace Macaulay - MedImmune released in the run up to the Immuno-Oncology Conference, 26-27 September, London.

LONDON, LONDON, UNITED KINGDOM, July 9, 2018

/EINPresswire.com/ -- SMi is proud to host the inaugural [Immuno-Oncology conference](#) this Autumn on 26 - 27 September 2018 in London, UK, with a focus on propagating thought-provoking discussions on novel targeted cancer therapies.



EXCLUSIVE CONTENT 

Q&A with:  **Grace Macaulay**
MedImmune

What do you see as the greatest hurdle to developing novel and effective Immunotherapies to treat cancer?

Immuno - Oncology Conference
26 - 27 SEPT 2018
London, UK

"The greatest hurdle is the lack of 'perfect' cellular or animal models that could be used to determine not only efficacy but safety before initiating first in man studies." #immunooncologySMi

www.immuno-oncology-conference.com [Read Full Q&A](#)

interview with Grace Macaulay - MedImmune

SMi Group caught up with expert speaker Grace Macaulay, Global Safety Physician, Patient Safety-Oncology, MedImmune to discuss the challenges associated with developing novel and effective Immunotherapies as cancer treatments, her role in MedImmune, and the future of Immuno-Oncology.

Dr Grace Macaulay MBBS, Dip. Pharm Med is a senior safety Physician with MedImmune (Part of AZ). She joined MedImmune in 2014 and has been working on checkpoint inhibitors since then. Prior to MedImmune, she was head of oncology within Patient safety at Ipsen and Mundipharma (Part of NAPP). Dr Macaulay has over 20 years clinical experience in Haematology and Oncology.

SMi: What is your role and what do you hope attendees to take away from your talk?

Grace Macaulay: My role is global safety physician within IO developmental franchise. The take home message is that as we combine various novel therapies in cancer treatment, we need to be aware of the known and unknown safety of these combinations that could have great impact on the patient wellbeing or quality of life.

SMi: What do you see as the greatest hurdle to developing novel and effective Immunotherapies to treat cancer?

Grace Macaulay: The greatest hurdle is the lack of 'perfect' cellular or animal models that could be used to determine not only efficacy but safety before initiating first in man studies.

Dr Macaulay will be presenting [on day two of the conference](#) on Key safety challenges in cancer immunotherapy clinical trials, where she will explore Immunotherapy past, present, and future, checkpoint inhibitors, key safety challenges: immune-mediated AEs, ESMO/ASCO guidelines and the way forward: getting the right balance.

Also presenting on the topic of Checkpoint Inhibitors, on day one of the Immuno-Oncology Conference, are expert speakers James Legg, Vice President R&D, Crescendo Biologics Ltd, and Loui Madakamutil, Vice President, Discovery and Research, Nektar Therapeutics. Mr Legg is set to present on “Targeting immune checkpoints with Humabody VH therapeutics”, whilst Mr Madakamutil will discuss “Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-biased cytokine”.

The full interview is available at <http://www.immuno-oncology-conference.com/ein>

In addition, interested parties can view other exclusive content and the latest event agenda, as well as book their place for the conference.

Twitter - [@SMIpharm](#) & #immunooncologysmi

LinkedIn - SMI Pharma

CONTACT:

+44 (0)20 7827 6000

ldurneva@smi-online.co.uk

Luda Durneva

SMi Group

2078276000

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.